Wellness Peptides and Cancer Risk: The ECRI/ISMP 2026 Warning and Oncological Facts
In this article
Are “Wellness Peptides” Returning to Pharmacies? The ECRI/ISMP May 2026 Warning and Overlooked Cancer Risks from an Oncology Perspective
In December 2023, the FDA banned a substantial proportion of these peptides, preventing licensed pharmacies from producing them. But on February 27, 2026, Health Secretary Robert F. Kennedy Jr. announced on Joe Rogan’s podcast that the ban on 14 peptides would be lifted. In April 2026, this became federal policy. On July 23-24, 2026, an FDA committee will vote on the fate of seven peptides (BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax).
Against this backdrop, ECRI and ISMP issued a joint warning on May 5, 2026: because the policy change was not supported by new clinical evidence, it does not mean these peptides are safe. Purity test results ranging from 5-75%, arsenic and lead contamination, and reported serious adverse effects — cardiac events, kidney dysfunction, infection, and a particularly important concern for readers interested in oncology, melanoma — are at the heart of the warning.
In this article, we will do three things: (1) summarize the main findings of the ECRI/ISMP report; (2) examine the biological effects of these peptides from an oncology perspective — because the general press does not discuss them in this context, although angiogenesis, the IGF-1 pathway, claims of telomerase activation, and melanoma risk are critical for cancer patients; (3) look at the peptide market in Türkiye and how to inquire about their use in clinical practice.
Reopening the gap in pharmacy regulation
ECRI and ISMP are two leading patient safety organizations in the United States. ECRI is recognized as a “Patient Safety Organization” by the federal agency AHRQ; ISMP is an affiliated organization that monitors medication errors. The two issued a joint warning on May 5, 2026. The main findings are as follows:
MAIN FINDINGS OF THE REPORT — MAY 5, 2026
- No clinical evidence. The vast majority of peptides sold in the wellness market have not been adequately tested in humans. For most, including BPC-157, published research is limited to animal models; in humans, there is not even a phase 1 safety study.
- Purity problems. Previous test results for peptides from the gray market showed purity levels fluctuating between 5% and 75% . Some samples contained arsenic and lead above the safety limits established for injectable medications.
- A gap in regulation. “Wellness” companies selling peptides are not overseen by any regulatory organization. According to ISMP president Rita Jew, this recalls the NECC fungal meningitis outbreak in 2012 — contaminated pharmacy products caused 64 deaths and more than 750 illnesses in the United States.
- Serious adverse effects. The report documents cases of cardiac events, kidney dysfunction, melanoma, and infection associated with peptide use.
- Access without a prescription. Patients can buy these substances online without a prescription, pharmacist oversight, or quality testing. The “for research use only” label shifts legal responsibility from the seller to the consumer.
From the ban in 2023 to the return in 2026
The policy landscape on this issue changed rapidly. Let us look at the key milestones:
TIMELINE OF PEPTIDE REGULATION
- December 2023: The FDA placed 19 peptides on the prohibited list. Licensed pharmacies were banned from preparing substances such as BPC-157, TB-500, CJC-1295, and ipamorelin. Production shifted to the “gray market” — online sales labeled “for research use only.”
- February 27, 2026: Health Secretary RFK Jr. announced on Joe Rogan’s podcast that the ban on 14 peptides would be lifted. His rationale was his own experience of healing from an injury and “redirecting demand from the black market into legal channels.”
- April 2026: The FDA announced that 7 of the 14 peptides — BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax — would be put to a committee vote. The other 5 substances were deferred until February 2027. Five peptides (Cerebrolysin, Follistatin 344, myostatin inhibitors, PE-22-28, and especially Melanotan II) will remain prohibited — the reason for Melanotan II is clear: melanoma risk.
- May 5, 2026: The ECRI/ISMP white paper was published.
- July 23-24, 2026: The FDA committee will vote. If approved, BPC-157 and the other six peptides will begin to be prepared on prescription at licensed pharmacies.
- Expected practical availability: Late 2026 - early 2027. But take note: availability through pharmacies is not FDA approval. The production and sales channel becomes regulated; the level of clinical evidence remains the same.
This point needs emphasis: “lifting the ban” does not mean they are safe. Only the production channel becomes regulated. This is precisely the essence of the ECRI/ISMP warning — a policy change is no substitute for scientific validation.
What do these peptides mean for cancer biology?
The discussion circulating in the general press — purity, contamination, and pharmacy regulation — is valid but incomplete. For readers interested in oncology, the main issue is different: the biological effects of these molecules open up potential pathways that could fuel cancer growth. Below, we examine the specific cancer-related risks of the five most commonly encountered peptides.
BPC-157 HIGH LEVEL OF CONCERN
A fragment of a stomach-protective protein consisting of 15 amino acids. VEGF (vascular growth factor) and FGF (fibroblast growth factor) release is increased. This supports the formation of new blood vessels (angiogenesis) during tissue healing.
For a tumor, angiogenesis is a building block of growth and metastasis. This is Folkman’s fundamental hypothesis from 1971 — one of the cornerstones of modern oncology. Approved cancer drugs such as bevacizumab and ramucirumab work in precisely the opposite direction, by blocking blood vessel formation. BPC-157 does precisely the opposite. The possibility that it could “feed” subclinical micrometastases in an individual with a tumor or cancer in remission is a mechanistic concern. No study demonstrates direct carcinogenesis, but the theoretical risk to existing tumor cells is substantial.
TB-500 HIGH LEVEL OF CONCERN
The active fragment of the thymosin beta-4 protein, consisting of 17 amino acids. It sequesters intracellular actin; it increases cell migration, angiogenesis, and inhibition of apoptosis.
Thymosin beta-4 is naturally overexpressed in tumor types such as colorectal, hepatocellular, lung, and breast cancer ; a strong correlation has been found between this overexpression and poor prognosis, an aggressive phenotype, and metastasis (Kobayashi 2002, Cancer; Cha 2003, Br J Cancer). Administering TB-500 externally could give tumor cells more of this property. Its use is particularly risky for a patient with active cancer or cancer in remission.
EPITALON (KHAVINSON TETRAPEPTIDE) CONTROVERSIAL
A peptide consisting of four amino acids (Ala-Glu-Asp-Gly). Developed by Russian gerontologist Vladimir Khavinson during the 1980-2000s. The marketing claim is that, by activating the telomerase enzyme , it lengthens telomeres at the ends of chromosomes.
If the claimed telomerase activation is true, it creates a major cancer problem. This is because telomerase activation is the mechanism by which cancer cells become immortal. Normal cells die when they reach their division limit (the Hayflick limit); cancer cells overcome this limit by reactivating telomerase. Telomerase is active in approximately 90% of human cancers, but in fewer than 1% of normal cells. Modern oncology targets the opposite: the telomerase inhibitor imetelstatis in phase 3 for the treatment of MDS. Thus, the effect claimed for Epitalon points in precisely the opposite direction from contemporary cancer pharmacology. The claim has not been scientifically validated; if it is true, it is concerning, and if it is not, the patient loses both money and time.
GROWTH HORMONE SECRETAGOGUES HIGH LEVEL OF CONCERN
CJC-1295 is an analog of growth hormone-releasing hormone (GHRH); ipamorelin and GHRP-2/6 are ghrelin receptor agonists. All of them increase the release of growth hormone from the pituitary gland and, consequently, the production of IGF-1 by the liver.
IGF-1 is one of the oldest and most firmly established mitogenic pathways in cancer biology. In prospective cohort studies, high IGF-1 levels were associated with a significant increase in the risk of colorectal, prostate, and breast cancer (Renehan’s 2004 Lancet meta-analysis). The strongest human evidence for this is: Laron syndrome — individuals with congenital GH/IGF-1 deficiency have an extremely low cancer incidence (Guevara-Aguirre 2011, Sci Transl Med). The administration of exogenous GH and GH secretagogues, particularly in cancer patients and older populations, has long been regarded as controversial by the clinical oncology community.
MELANOTAN II CRITICALLY HIGH RISK
An analog of alpha-MSH (melanocyte-stimulating hormone). It strongly activates the MC1R receptor on melanocytes, increasing melanin production and skin pigmentation.
Melanotan II is the only peptide directly associated with melanoma cases in the literature. Cardones and Grichnik (2009, Arch Dermatol), Hjuler and Lorentzen (2014, Dermatology), and subsequent case reports documented dramatically darkening or newly appearing atypical moles and melanoma cases in individuals using Melanotan II. The mechanism: continuous proliferative stimulation of melanocytes facilitates the emergence of more aggressive behavior in existing moles or melanoma precursor cells. The FDA excluded Melanotan II from the May 2026 list — meaning the ban will continue. This signals that the authority explicitly acknowledges melanoma risk. It is widely sold through fitness and cosmetic channels in Türkiye; it is particularly risky in high-UV areas along the Mediterranean coast.
The general picture: these peptides create a cellular “growth storm”
The five peptides above share the following feature: they all work through tissue healing, cell proliferation, or endocrine pathway activation . In a healthy young individual, these pathways respond predictably.
But in an individual carrying subclinical micrometastases or undergoing follow-up for cancer remission, these growth-stimulating signals are also transmitted to existing malignant cells. In other words, a peptide “heals the wound,” but it may also “awaken dormant tumor cells.” This mechanistic concern calls for a specific warning for cancer survivors.
One point matters for cancer epidemiology in Türkiye: the annual incidence of melanoma is 2,5-3,5 / 100.000, below the EU average but increasing. It is higher along the Mediterranean coast (Antalya, Muğla, İzmir) and in high-UV areas of Central Anatolia. Turkish tanning culture — intense sun exposure during the summer — is already a major risk factor; adding Melanotan II compounds the risk. Seeking “easy tanning” for cosmetic purposes is an active consumer behavior that unknowingly increases melanoma risk.
“Are you using peptides?” is now part of routine history-taking
For readers of drozdogan.com, Bader’s warning points to a practical category of five questions for history-taking:
SUGGESTED QUESTIONS TO ADD TO THE ONCOLOGY PATIENT HISTORY
- Which peptide are you using? Name, dose, frequency, and route of administration. The patient may not know the term “wellness peptide” — an alternative is: "Have you used BPC-157, TB-500, growth hormone supplements, or Melanotan?"
- Where did you obtain it? A pharmacy, the internet, a fitness center, or a social media seller. This is critical for assessing contamination risk.
- What are the duration and frequency? Total exposure, the “cycle” approach (take it for X days, pause for X days), and other substances used concurrently (anabolic steroids, testosterone, peptide combinations).
- Do you have symptoms? Injection-site reactions, fever, signs of infection (most common with peptides), new skin changes (critical for Melanotan II — a new or changing mole calls for a dermatology consultation), chest pain, edema, and fatigue.
- Are you receiving active treatment? If yes — peptide use during chemotherapy, immunotherapy, or targeted therapy must not be recommended. Interactions and toxicity are unpredictable.
- Eastern Europe and Russia: Epitalon and other Khavinson peptides are common.
- The Middle East and the Gulf: Melanotan II and growth hormone secretagogues are popular among male patients.
- Central Asia (Kazakhstan, Uzbekistan, Kyrgyzstan): The fitness-focused BPC-157 + TB-500 “Wolverine Stack” is on the rise.
This story is particularly important for cancer survivors. It is a clinical fact that individuals diagnosed and treated for cancer who are in remission frequently experience fatigue, muscle loss, joint pain, reduced libido, and weight management problems . These symptoms draw individuals toward the marketing messages of wellness peptide sellers — particularly BPC-157 (for chronic pain), CJC-1295/ipamorelin (for muscle and fat composition), and TB-500 (for recovery after chemotherapy).
However, the biology of cancer survivors makes the peptide risk profile particularly high. There are four specific concerns:
FOUR LAYERS OF PEPTIDE RISK IN CANCER SURVIVORS
- Awakening dormant tumor cells. Many cancer types (hormone-positive breast cancer, prostate cancer, and melanoma) can recur years later; this is explained by the activation of dormant micrometastases. Peptides that stimulate angiogenesis and growth factors have the potential to awaken these dormant cells.
- A background predisposition to secondary malignancy. After radiotherapy and certain chemotherapy regimens (particularly alkylating agents), the risk of secondary cancer is higher than in the general population. Adding mutagenic or proliferative signals presents an additional risk in this setting.
- Interaction with immunotherapy. In patients receiving or previously treated with immune checkpoint inhibitors, immunomodulatory peptides (thymosin alpha-1, KPV, etc.) have an unknown interaction profile.
- Endocrine interactions in hormone-dependent tumors. Activation of the GH/IGF-1 pathway is particularly problematic for survivors of breast, prostate, and endometrial cancer.
This is an important topic on modern oncology’s “survivorship” (follow-up after treatment) agenda: preventing patients from turning to gray-market peptides to improve their quality of life after treatment and offering them evidence-based alternatives . These alternatives — regular resistance exercise, cancer-specific rehabilitation programs, physical therapy, nutritional counseling, appropriate pain management, and psychosocial support — may seem less “enchanting,” but they are both safe and effective.
⚡ WHY DOES IT MATTER?
In May 2026, the joint white paper from ECRI and ISMP clearly established that the wellness peptide market lacks clinical evidence. The policy change under RFK Jr.’s administration (lifting the ban on 12 peptides and the FDA committee vote in July 2026) will facilitate access to these substances through prescription channels — but does not show that they are safe. Of particular importance to readers interested in oncology: BPC-157 and TB-500 activate angiogenesis/migration; GH secretagogues activate the IGF-1 pathway; Epitalon is a claimed telomerase activator; Melanotan II has been documented in connection with melanoma risk. All generate specific biological concerns for cancer patients and survivors.
✅ THE ECRI/ISMP WARNING AND THE EVIDENCE
The joint warning of two independent patient safety organizations carries considerable authority. Purity of gray-market peptides fluctuates from 5-75%, with arsenic and lead contamination and parallels to the 2012 NECC fungal meningitis outbreak. Reported serious adverse effects include cardiac events, kidney dysfunction, melanoma, and infection. The policy change was not supported by new clinical evidence — RFK Jr.’s statement on Joe Rogan’s podcast is a political/populist rationale, not scientific validation.
⚠️ ONCOLOGY-SPECIFIC RISK
BPC-157 and TB-500: increased VEGF/FGF and the association between thymosin-beta-4 overexpression and a metastatic tumor phenotype (Kobayashi 2002, Cancer; Cha 2003, Br J Cancer). Epitalon: the claimed telomerase activation is the mechanism by which cancer cells become immortal — modern oncology targets the opposite (inhibitors such as imetelstat). CJC-1295/ipamorelin/GHRPs: GH-IGF-1 pathway activation; in prospective cohorts, IGF-1 is associated with colorectal, prostate, and breast cancer risk (Renehan 2004, Lancet meta-analysis). Melanotan II: a risk documented in melanoma case reports (Cardones-Grichnik 2009, Arch Dermatol; Hjuler-Lorentzen 2014, JAMA Dermatol) — the FDA is maintaining the ban.
🩺 IMPLICATIONS FOR CLINICAL PRACTICE
At Memorial Göztepe and other oncology centers, peptide use should be routinely asked about during history-taking: name, dose, duration, source, and adverse effects. Peptide use must not be recommended for patients receiving active oncological treatment (chemotherapy, immunotherapy, targeted therapy) — interactions and toxicity are unpredictable. A special warning for cancer survivors: the risk of stimulating dormant micrometastases, proliferative signals in a setting predisposed to secondary malignancy, and GH/IGF-1 endocrine interactions in hormone-dependent tumors. In Türkiye, Melanotan II is widely used for cosmetic purposes, particularly in high-UV areas along the Mediterranean coast — dermatology consultation and skin screening should be recommended. Regional patterns for international patient coordinators: Epitalon in Eastern Europe/Russia, Melanotan II and GH secretagogues in the Gulf, and the BPC-157+TB-500 Wolverine Stack in Central Asia. Evidence-based alternatives should be recommended: resistance exercise, cancer rehabilitation programs, nutritional counseling, appropriate analgesia, and psychosocial support.
❓ QUESTIONS FOR THE FUTURE
How will pharmacy access to peptides change after the FDA committee vote on July 23-24, 2026? Will Category 1 status encourage new controlled clinical trials, or will the level of evidence remain low? When will the impact of peptide use on oncological outcomes in active cancer patients and survivors be studied prospectively? How will clinical guidelines specifically for cancer survivors address peptide use? What regulatory approach will Türkiye’s Ministry of Health adopt toward the wellness peptide market? How does Melanotan II use affect melanoma epidemiology in the Turkish population along the Mediterranean coast — is a national epidemiological study needed?
References
- ECRI and Institute for Safe Medication Practices (ISMP). Patients Using Wellness Peptides Have No Reliable Information About Whether They Are Safe or Effective. Joint white paper. Willow Grove, PA: PRNewswire, May 5, 2026.
- Salahi L. Wellness Peptides Lack Reliable Safety Information, Watchdog Warns. Medscape Medical News, May 12, 2026.
- Kennedy RF Jr. The Joe Rogan Experience podcast Episode #2461, February 27, 2026. (The first announcement of moving 12 peptides from Category 2 to Category 1.)
- U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee (PCAC) meeting notice for July 23-24, 2026. Silver Spring, MD: FDA, April 2026.
- Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971;285(21):1182-1186.
- Kobayashi T, Okada F, Fujii N, et al. Thymosin-beta4 regulates motility and metastasis of malignant mouse fibrosarcoma cells. American Journal of Pathology 2002;160(3):869-882.
- Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute 2003;95(22):1674-1680.
- Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363(9418):1346-1353.
- Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 2011;3(70):70ra13.
- Cardones AR, Grichnik JM. α-Melanocyte-stimulating hormone-induced eruptive nevi. Archives of Dermatology 2009;145(4):441-444.
- Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology 2014;228(1):34-36.
- Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections — 2012 (NECC outbreak). Final report. Atlanta, GA: CDC, 2013.
- Türk Dermatoloji Derneği ve Türk Estetik Plastik Cerrahi Derneği. Melanotan II kullanımı hakkında ulusal uyarı bildirileri. Accessed: 2026.
This article is intended as medical news/information and does not provide individual treatment guidance. Wellness peptides (including BPC-157, TB-500, Epitalon, Melanotan II, CJC-1295, ipamorelin, KPV, MOTS-c, DSIP, and Semax) have not been approved for human use by the United States FDA or the Republic of Türkiye Ministry of Health. Obtaining these substances without a prescription or through the gray market carries legal and clinical risks. Patients receiving active oncological treatment should not use these substances without the approval of their treatment team. For cancer survivors, potential angiogenesis, IGF-1 pathway activation, claims of telomerase activation, and immune modulation create specific biological concerns. Peptide use should be a routine history-taking question in oncology consultations. The ECRI/ISMP white paper was published on May 5, 2026, and Lara Salahi’s Medscape report on May 12, 2026. RFK Jr.’s statement on the Joe Rogan Experience was on February 27, 2026. The FDA PCAC vote is scheduled for July 23-24, 2026.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.